4:01 PM
Sep 13, 2017
 |  BC Extra  |  Clinical News

Amicus' SD-101 misses in Phase III for skin blistering disorder

Amicus Therapeutics Inc. (NASDAQ:FOLD) said SD-101 missed the two primary endpoints of the Phase III ESSENCE trial to treat simplex, recessive dystrophic or junctional non-Herlitz epidermolysis bullosa (EB). Based on the data, the company said it has "no current plans to invest in any additional clinical studies or commercial preparation activities for SD-101."

Read the full 255 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >